Preclinical Testing of a Novel Extracorporeal Membrane Oxygenation System in an Acute Cardiogenic Shock Animal Model

ABSTRACT Background Preclinical studies with appropriate large animal experimental models are critical to the development of extracorporeal membrane oxygenation (ECMO) technology. This study aimed to evaluate the safety and efficacy of a novel ECMO system, compared with a commercially available ECMO system, in a large animal model of acute cardiogenic shock (ACS). Methods Eight healthy pigs (3 months old) were randomly assigned to four experimental groups to compare a novel ECMO device (the Hui Sheng‐1), coupled with a modified centrifugal pump (CP‐1) ( n = 2) or a Maquet RF32 centrifugal pump ( n = 2) with a commercial ECMO device, coupled with either a CP‐1 ( n = 2) pump or a RF32 pump ( n = 2) Following general anesthesia, a median sternotomy and central cannulation (aorta‐right atrium) was performed, ACS was induced, and a veno‐arterial ECMO model was established and operated continuously for 48 h. During the experiment, the rotation, flow rate, and mean arterial pressure were recorded, and complete blood cell counts, blood‐gas analysis, coagulation function, free hemoglobin concentration, and inflammatory factor concentrations were monitored. Results ACS was induced and ECMO was successfully performed in all animals without serious bleeding, thrombosis, instrument failure, or other adverse events. There was no statistically significant difference in free hemoglobin concentration between the experimental groups at every recorded time point ( p > 0.05). The ECMO rotation and flow rate were stable in all groups, and there was no significant difference in the mean arterial pressure or lactate level between the groups ( p > 0.05). IL‐1β, IL‐6, and IL‐10 levels were significantly lower in the CP‐1 groups than in the RF32 centrifugal pump groups ( p < 0.05), while there was no significant difference in TNF‐α, and IL‐8 levels ( p > 0.05). Conclusions Our data suggest that the novel ECMO device is safe and efficient during short‐term use in a large animal model of ACS.

Authors

Institutions

Publication Details

Journal
Organ medicine.
Published
2025-03-01
DOI
https://doi.org/10.1002/orm2.70000
Primary Topic
Mechanical Circulatory Support Devices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Preclinical Testing of a Novel Extracorporeal Membrane Oxygenation System in an Acute Cardiogenic Shock Animal Model

Rong Wang, Chenqi Zhu, Yue Sheng, Hua Shen et al.
Organ medicine.
Mechanical Circulatory Support Devices
article

Preclinical Testing of a Novel Extracorporeal Membrane Oxygenation System in an Acute Cardiogenic Shock Animal Model

Rong Wang, Chenqi Zhu, Yue Sheng, Hua Shen, Yanling Ren, Shaowei Sang, Tao Zhang, Jian Xu, Mingyan Wang, Shiyong Dong, M. Ren
article en

Abstract

ABSTRACT Background Preclinical studies with appropriate large animal experimental models are critical to the development of extracorporeal membrane oxygenation (ECMO) technology. This study aimed to evaluate the safety and efficacy of a novel ECMO system, compared with a commercially available ECMO system, in a large animal model of acute cardiogenic shock (ACS). Methods Eight healthy pigs (3 months old) were randomly assigned to four experimental groups to compare a novel ECMO device (the Hui Sheng‐1), coupled with a modified centrifugal pump (CP‐1) ( n = 2) or a Maquet RF32 centrifugal pump ( n = 2) with a commercial ECMO device, coupled with either a CP‐1 ( n = 2) pump or a RF32 pump ( n = 2) Following general anesthesia, a median sternotomy and central cannulation (aorta‐right atrium) was performed, ACS was induced, and a veno‐arterial ECMO model was established and operated continuously for 48 h. During the experiment, the rotation, flow rate, and mean arterial pressure were recorded, and complete blood cell counts, blood‐gas analysis, coagulation function, free hemoglobin concentration, and inflammatory factor concentrations were monitored. Results ACS was induced and ECMO was successfully performed in all animals without serious bleeding, thrombosis, instrument failure, or other adverse events. There was no statistically significant difference in free hemoglobin concentration between the experimental groups at every recorded time point ( p > 0.05). The ECMO rotation and flow rate were stable in all groups, and there was no significant difference in the mean arterial pressure or lactate level between the groups ( p > 0.05). IL‐1β, IL‐6, and IL‐10 levels were significantly lower in the CP‐1 groups than in the RF32 centrifugal pump groups ( p < 0.05), while there was no significant difference in TNF‐α, and IL‐8 levels ( p > 0.05). Conclusions Our data suggest that the novel ECMO device is safe and efficient during short‐term use in a large animal model of ACS.

Organ medicine.Vol. 2(1)
Academy of Military Medical Sciences (CN), Chinese PLA General Hospital (CN), Tibet Autonomous Region People's Hospital (CN)
Openalex Percentile: Top 95%
Mechanical Circulatory Support Devices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.